

Bavarian Biotech News

July 2019



Bavaria

Tradition
meets

FORUM
Science & Health

Innovation



Panel discussion on antibiotic resistances, supported by bayresq.net

Dear readers,

at our successful event FORUM Science & Health we had excellent talks and stimulating discussions about the “medicine of the future” and its challenges. Enjoy reading more about the conference and other news and events in our current newsletter. Have a nice summer!

Your Bio^M-Team



Spotlight Forum Science & Health	Page 2	Bavaria worldwide	Page 5
Selected recent headlines	Page 3	Technologies you must have seen	Page 6
BioEntrepreneurs in Bavaria	Page 4	Events and Contact	Page 7

2nd Forum Science & Health provides new impulses for personalized medicine

The 2nd [FORUM Science & Health](#) on July 3/4 in Fürstenfeldbruck near Munich brought together more than 300 participants from science, clinics, network and patient organizations as well as industry to highlight current topics and trends in health research. This year's conference focused on *system medicine* as the necessary basis for personalized medicine. With the topics autoimmune diseases, cancer, antibiotic resistance, data management, biomarkers and nutrition, the FORUM Science & Health highlighted the new challenges our society and our healthcare system is facing. [Read more...](#)



State Secretary Roland Weigert, StMWi (left) and Prof. Horst Domdey, Managing Director Bio^M.

Lectures and Panel Discussions



watch our video: [Bio^M FORUM Science & Health 2019](#)



Networking



Exhibition and Postersession



FORUM
Science & Health

www.forum-science-health.org

2018: a record year for Invest in Bavaria

2018 was the most successful year in the history of the Bavarian business promotion agency "Invest in Bavaria". 146 successfully managed projects, 121 of which were relocation cases, are proof of Invest in Bavaria's outstanding commitment. This created 1,817 new jobs across Bavaria and secured a further 710. Among foreign investors, the USA ranked first ahead of Japan and Great Britain. Overall, the origin of the investments is distributed relatively evenly across the country which suggests that Bavaria is an attractive location for innovation. The new settlements were spread across all seven administrative districts, although the interest of investors in Munich and Upper Bavaria has remained above average.

www.invest-in-bavaria.com



Kress becomes new CEO of MorphoSys

The Supervisory Board of MorphoSys AG has appointed Dr. Jean-Paul Kress, M.D., as its new CEO following Simon Moroney who will step down as CEO on September 1, 2019. Dr. Kress brings over 20 years of experience in the pharmaceutical and biotechnology industry, with a strong track record of commercial and operational leadership in various senior management roles in North America and Europe.



Dr. Jean-Paul Kress
© MorphoSys AG

His focus has been on operations, corporate development and especially the commercialization of innovative products addressing unmet medical needs across diverse disease indications.

[Read more...](#)



MetaHeps part of TransBioLine

MetaHeps is part of the European IMI-Project Translational Safety Biomarker Pipeline (TransBioLine), which started on April 15, 2019. The project is a five-year program to generate exploratory and confirmatory data supporting regulatory qualification and acceptance of novel safety biomarkers for five target organ systems for application in drug development. The Martinsried startup company MetaHeps was chosen to perform causality assessment of liver injury by drugs with its unique *in vitro* test using patient derived blood cells.

[Read more...](#)



TUM and LMU awarded as Universities of Excellence

The Ludwig-Maximilians-Universität München and the Technical University of Munich have been awarded as University of Excellence. The Excellence Commission selected ten universities and one university consortium of excellence. Each awarded university will receive between 10 and 15 million euros annually. After seven years, the funding will be continued given a successful interim evaluation.

[Read more...](#)

bluebird bio's gentherapy Zynteglo™ will be produced by apceth

apceth Biopharma GmbH from Ottobrunn/Munich becomes commercial manufacturer in Europe for the gene therapy Zynteglo™. The product from the US company bluebird bio for the treatment of transfusion-dependent β -thalassaemia received conditional marketing authorisation from the European Commission (EC). As a pioneer in the field of cell therapy and regenerative medicine, apceth Biopharma is a certified partner for the development and production of cell and gene therapies for various customers. [Read more...](#)



© apceth Biopharma GmbH

Meet all stakeholders of the bioentrepreneurial and health tech ecosystem:

At the [BioEntrepreneurship Summit 2019](#) taking place in **Munich on October 15 and 16**, we bring together founders, startup enthusiasts, experienced entrepreneurs, corporates and investors to foster the exchange of knowledge, to inspire, to empower, and to celebrate life science entrepreneurship.



- panel discussions
- workshops and lectures
- pre-seed and start-up showcases
- m⁴ Award ceremony

Confirmed speakers include:

- Alexandra Bause, Apollo Ventures
 - Gordon Euler, APEX Ventures
 - Marc Filerman, German Accelerator Life Sciences
 - Lena Krzyzak, High Tech Gründerfonds
 - Mark Leruste, The Unconventionalists
 - Christian Schetter, Arix Bioscience
 - Moritz Weisbrodt, Kaia Health
- and many more...

EIT Health BioEntrepreneurship Lab Oxford-Munich 2019

On July 12, the final of the [EIT Health BioEntrepreneurship Lab Oxford-Munich 2019](#) took place at Bio^M in Martinsried near Munich with the awarding of the winners. Ten startup teams from all over Europe had designed and validated their innovative biotech business concepts during the three-month programme under the leadership of Bio^M and Oxford University Innovation and the Entrepreneurship Center of the University of Oxford. With a pitch, all teams presented the results of their work at the "Acceleration Day". DoDerm from Munich/Utrecht reached first place with its pathogen-specific, sprayable skin therapy for the local treatment of multi-resistant bacterial inflammations.



DoDerm from Munich/Utrecht reached first place at the BioEntrepreneurship Lab 2019 with its pathogen-specific, sprayable skin therapy for the local treatment of multi-resistant bacterial inflammations. © Bio^M

[Read more...](#)



EIT Health is supported by the EIT, a body of the European Union



Start.Smart.Global – 11 European companies selected for roadshow to Japan and Korea

Following an intensive selection process through a dedicated sector-specific jury, eleven European companies are laureates of the 2019 roadshow of the “Start.Smart.Global” programme. They will benefit from a unique training programme including one week to Japan and one week to Korea.

The programme will enable the start-ups & SMEs to enter two recognised Asian innovation hubs which can act as major stepping stones into the Asian market and initiate significant collaboration opportunities with qualified stakeholders.

Japan has the world’s 2nd largest healthcare market and ranks amongst Europe’s top 5 pharmaceutical trading partners. And South Korea is nurturing a culture of innovation and attractive regulatory environment to place itself in the top ranking of global health care hubs.

[Read more...](#)



Start.Smart.Global Korea training in Paris with six of the European companies © Bio^M



Start.Smart.Global



EIT Health is supported by the EIT, a body of the European Union



HORIZON 2020 project Peer2scale

Peer2scale, an HORIZON 2020 project, is a peer-learning action between four regional health agencies acting as clusters. [Eurasanté](#) (Hauts-de-France), [Bio^M](#) (Bavaria), [Biocat](#) (Catalonia) and [Lifetech Brussels](#) (Brussels) support services to their network of health SMEs. Peer2Scale-Health is focusing on actions to assess the quality of the partners’ services to health entrepreneurs (and young SMEs), the way they deliver these, and how to improve them or design new and common innovation support services.

[Read more...](#)



Co-funded by the Horizon 2020 programme of the European Union

Get in touch with the Bavarian biotech community

Osaka BioPharma Partnering Event

October 8, 2019



BioJapan 2019

October 9-12

Asia’s Premier Partnering Event for the Global Biotechnology Industry

BIO-EUROPE @

November 11–13, 2019

Hamburg, Germany



Bavarian joint booth at BIO-Europe

- 2 bind GmbH
- Assay.Works GmbH
- Cherry Biolabs
- Coriolis Pharma Research GmbH
- i.DRAS GmbH/HWI group
- MEDIZONE GERMANY GMBH
- NDA Regulatory Service GmbH
- OmicScouts GmbH
- PAN Biotech GmbH

All Company Profiles of the Bavarian Biotech Cluster in our annual report:



www.bio-m.org/database

Biomax Informatics AG

Biomax provides computational solutions for better decision making and knowledge management in the life science industry. They focus on integrating information to enable a knowledge-based approach to develop innovative life science products. Their BioXM™ Knowledge Management Environment combines software products and knowledge resources to help customers eliminate the coding process, slash the implementation time of complex projects, harness the information overload and distill critical insights from data. The Viscovery® data mining software complements the BioXM system with tools to identify and validate diagnostic biomarkers.

Biomax's worldwide customers include companies and research organizations in healthcare, drug discovery, diagnostics, fine chemicals, food and plant production.



www.biomax.com

MLL Münchner Leukämielabor GmbH

MLL Münchner Leukämielabor is a leading institution for leukemia diagnostics and research, operating within a highly innovative environment. United within a single facility, the interdisciplinary structure guarantees valid, comprehensive and prompt diagnosis thanks to a steady flow of information between the following departments: cytomorphology,

chromosome analysis, immunophenotyping, cytogenetics, FISH, molecular genetic techniques such as PCR and next-generation sequencing. The combination of routine diagnostics, science, automation and digitization guarantees high-quality diagnosis that gives medical professionals an essential foundation to ensure ideal patient care.



Prof. Torsten Haferlach,
CEO, MLL Münchner
Leukämielabor GmbH

The current trend in medical science is very clearly towards artificial intelligence. MLL Münchner Leukämielabor is making full use of these new technologies. Having sequenced 5000 genomes, we are using AI to analyse the acquired data and, with the knowledge gained, enhance diagnostics and discover new pathways. We are convinced that AI will become an important part of routine diagnostic procedures in the next five years, meaning that cases of leukaemia will be easier to identify, and personalized forms of treatment can be deployed with greater efficacy.

The MLL Münchner Leukämielabor GmbH has made it into the top of the 26th edition of the **TOP 100 innovation competition.**



Upcoming Bio^M Events

BioEntrepreneurship Summit 2019
create the future of medicine
Munich, October 15 - 16, 2019

DigiMed Bayern
für die Medizin der Zukunft

DigiMed Bayern Symposium 2019
Translationale Medizin im digitalen Zeitalter

Programm & Registrierung:
www.digimed-bayern.de/symposium-2019.html

6. November 2019
Deutsches Herzzentrum München

Save the Date 2020

BIO-Europe

26 – 28 October 2020, Munich

Europe's Largest Life Science Partnering Event to be held in Bavaria's capital!



more events: www.bio-m.org/en/events

Contact

Bio^M Biotech Cluster Development GmbH
Am Klopferspitz 19a
82152 Martinsried, Munich, Germany

www.bio-m.org
 +49 (0) 89 89 96 790
 info@bio-m.org

Follow us on:

Cluster Information



Dr. Georg Käab
Kaeab@bio-m.org

International Affairs



Dr. Stephanie Wehnelt
Wehnelt@bio-m.org

Founders & Investors



Christina Enke-Stolle, Enke-Stolle@bio-m.org,
Angelika Leppert, Leppert@bio-m.org
Dr. Petra Burgstaller, Burgstaller@bio-m.org